DEFA14A: Enhabit Defends Board Nominees Amid Proxy Fight, Cites Improved Performance and Strategic Vision

Enhabit urges stockholders to vote for its director nominees, highlighting recent performance improvements and strategic initiatives in response to a proxy contest by AREX Capital Management.

Summary

• Enhabit has released an investor presentation in connection with its upcoming Annual Meeting of Stockholders on July 25, 2024.
• The company is currently engaged in a proxy contest with AREX Capital Management, who are seeking to replace seven of the eight independent directors.
• Enhabit's board argues that AREX's proposal threatens the company's recent stabilization and that their nominees lack relevant industry experience.
• The company highlights recent performance improvements, including beating adjusted EBITDA consensus estimates for two consecutive quarters and reaffirming its full-year 2024 guidance.
• Home Health admissions are up, with non-Medicare admissions increasing by 25% and total admissions growing by 5.3% year-over-year.
• In Hospice, Enhabit reported 5.6% sequential growth in admissions in Q1 2024 and sequential census growth each month from January to May.
• The company's full-time nursing candidate pool increased over 30% year-over-year in Q1 2024, resulting in the addition of 151 net new full-time nurses.
• Enhabit's Board conducted a strategic review process that lasted nine months, engaging 38 potential counterparties, but received no formal proposals.
• The Board remains open to considering all potential paths to enhance stockholder value.
• Enhabit's Board recommends that stockholders vote for its nine director nominees on the YELLOW proxy card.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the reported improvements in performance and the board's confidence in its strategy. However, the proxy contest and the challenges faced since the spin-off temper the overall outlook.

Positives

• Enhabit has shown improved performance, beating adjusted EBITDA consensus estimates for two consecutive quarters.
• Home Health admissions are growing, particularly in the non-Medicare segment.
• Hospice admissions and census are also showing positive growth.
• The company has successfully increased its nursing staff.
• The Board has taken decisive actions to address challenges faced since the spin-off from Encompass Health Corporation, including forming a special technology committee and overseeing the finance organization.

Negatives

• Enhabit is facing a proxy contest from AREX Capital Management, which the company believes threatens its stability.
• The strategic review process did not result in any formal proposals.
• The company has faced challenges since its spin-off from Encompass Health Corporation.

Risks

• The proxy contest with AREX Capital Management could disrupt the company's operations and strategic plans.
• Regulatory changes and reimbursement rate fluctuations could impact the company's financial performance.
• The company faces risks related to attracting and retaining key personnel and healthcare professionals.
• Potential disruptions or breaches of information systems could negatively affect the company.
• The company's ability to successfully integrate technology into its operations is a risk factor.

Future Outlook

Enhabit believes it has the right strategy and director candidates to oversee growth and value creation initiatives. The company remains open to considering all potential paths to enhance stockholder value.

Management Comments

• The Enhabit Board and management team have successfully stabilized the business in the face of substantial industry and company-specific headwinds and positioned the Company to unlock shareholder value.
• AREX is pursuing its contest at exactly the wrong time and with candidates who are demonstrably inferior to the Company's nominees in terms of relevant industry experience, public company board experience, complementary skill sets and career accomplishments.
• AREX's campaign threatens the recent stabilization of the business.

Industry Context

The home health and hospice industry is facing headwinds, and Enhabit is working to navigate these challenges through strategic initiatives and innovation. The proxy contest highlights differing views on the best path forward for the company.

Comparison to Industry Standards

• It is difficult to compare Enhabit's performance directly to specific industry standards without more detailed financial data and competitor analysis.
• However, companies like Amedisys and LHC Group are major players in the home health and hospice space, and their performance metrics could be used as benchmarks.
• Comparing Enhabit's admission growth rates, EBITDA margins, and nursing staff levels to those of its peers would provide a more comprehensive assessment of its relative performance.

Stakeholder Impact

• The outcome of the proxy contest will significantly impact the company's direction and strategy, affecting shareholders.
• The company's performance and strategic initiatives will impact employees, patients, and other stakeholders.
• The company's ability to navigate industry challenges will affect its long-term viability and its ability to provide quality care.

Next Steps

• Stockholders will vote on the director nominees at the Annual Meeting on July 25, 2024.
• The company will continue to execute its strategic plans and monitor industry trends.
• Enhabit will continue to evaluate potential paths to enhance stockholder value.

Key Dates

Keywords

Enhabit, proxy contest, AREX Capital Management, home health, hospice, board of directors, stockholders, admissions, EBITDA, strategic review